Cybin Announces CDN$20 Million Bought Deal Offering Jan 18 • 4 min read Cybin Inc. announced that it has entered into an agreement with Canaccord Genuity Corp. to purchase 8,900,000 units of the company at a price of CDN$2.25 per unit for aggregate gross proceeds of CDN$20,025,000.
Journey Colab: Including Traditional Communities in the Plant-Based Medicine Boom Jan 15 • 7 min read One aspect of psychedelic and plant-based medicine that often gets overlooked by for-profit interests is the fact that many of these compounds are rooted in indigenous communities. For instance, the peyote ceremonies that help so many with PTSD and depression are based on traditional treatments that have been practiced in rare parts of the world…
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Jan 15 • 4 min read Seelos Therapeutics, Inc. announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience Jan 14 • 3 min read MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Novamind Expands Psychedelic Medicine Access in Utah Jan 13 • 2 min read Novamind Inc. announced the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah.